SCHEMBL9892800

SCHEMBL9892800

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1nc(-c2ccc(F)c(F)c2)cs1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.52
NPC1 O15118 2/20 0.52
MEN1 O00255 9/20 0.52
KMT2A Q03164 9/20 0.52
ALDH1A1 P00352 2/20 0.49
MAPK1 P28482 1/20 0.49
MAPT P10636 1/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
KCNQ1 P51787 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PSMD14 O00487 1/20 0.48
UCHL1 P09936 1/20 0.47
USP30 Q70CQ3 1/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13257815 0.94 KCNQ1 (0.56) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL16238050 0.94 KCNQ1 (0.56) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL9892928 0.86 SMN1; SMN2 (0.56) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL31197984 0.85 USP30 (0.62) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL31197947 0.84 RAB9A (0.52) RAB9ANPC1ALDH1A1MAPTKDM4E
SCHEMBL31198019 0.84 RAB9A (0.52) RAB9ANPC1ALDH1A1MAPTKDM4E
SCHEMBL31198062 0.84 RAB9A (0.52) RAB9ANPC1ALDH1A1MAPTKDM4E
SCHEMBL31198022 0.84 RAB9A (0.52) RAB9ANPC1ALDH1A1MAPTKDM4E
SCHEMBL16238849 0.84 KCNQ1 (0.60) NPC1MEN1KMT2AALDH1A1MAPT
SCHEMBL16238848 0.84 KCNQ1 (0.60) NPC1MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 RAB9A 1317/4885NPC1 1689/4885MEN1 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.